Introduction {#s1}
============

Pneumococcal pneumonia is the most common cause of childhood deaths in the developing world and among the top ten causes of death in aged populations worldwide; recently, antibiotic-resistant *S. pneumonia* strains have emerged [@pone.0009432-Nasrin1], [@pone.0009432-Hooper1], [@pone.0009432-Morita1], [@pone.0009432-Richter1]. Hence, vaccines against these strains are greatly needed. This study characterizes the HTL epitopes of a candidate pneumococcal vaccine antigen, PspA, which is a highly conserved, cell wall-associated surface protein that plays a major role in pneumococcal virulence by binding human lactoferrin and interferes with complement deposition on the bacterial surface [@pone.0009432-Bignell1]. During the course of invasive disease, antibodies against PspA peak during the convalescent phase, but CD4^+^ T cell help is required for optimal protective immune responses to PspA [@pone.0009432-Costantino1], [@pone.0009432-Alrutz1].

A central event in the adaptive immune response to invasive microorganisms is the specific recognition of processed antigens bound to the peptide-binding region of MHC class II molecules on the surface of antigen-presenting cells. These peptide antigens are subsequently detected by the T cell receptor (TCR) of CD4^+^ T cells, which proliferate, secrete cytokines, and differentiate into antigen-specific Th effector cells. To induce protective immunity, HTL epitopes contained in synthetic peptide vaccines must: (i) match those naturally presented to the immune system during infection, (ii) be recognized by the majority of the human population, and (iii) induce an appropriate effector immune response to eliminate the pathogen of interest. Single epitope-based vaccines may, however, have drawbacks. For example, the mono-specificity of the induced immune response might miss the emergence of sequence mutants that would potentially escape the vaccine\'s protective effect [@pone.0009432-Ertl1]. It is also unlikely that T cells from genetically distinct populations would recognize, and respond to a single peptide epitope.

These obstacles are secondary to the wide-ranging polymorphisms of HLA molecules that present antigenic peptides to T cells. Indeed, a unique set of epitopes from a given protein antigen will be presented to T cells of an individual bearing hundreds of unique HLA molecules. Additionally, some HLA molecules may not be able to bind to any of the peptides derived from a given protein [@pone.0009432-BrooksWalter1], [@pone.0009432-Sturniolo1]. The major challenge of peptide-based vaccines is the identification of one or more epitope(s) that bind to many HLA alleles and cover close to 100% of the genetically diverse human population [@pone.0009432-CunhaNeto1]. Thus, the identification of peptides that bind to multiple HLA types, the so-called "promiscuous" or "universal" epitope(s), could lead to effective coverage of the human population using peptide-based vaccine.

Until recently, the search for immunodominant peptides relied on the direct testing of overlapping peptides or peptide libraries. Fortunately, the identification of MHC binding motifs allowed for the prediction of potential T cell epitopes [@pone.0009432-Rammensee1], [@pone.0009432-Meister1]. To identify the immunodominant epitopes of PspA, we used *in silico* MHC affinity measurement methods using both affinity data from the Immune Epitope Database and Analysis Resource (IEDB) [@pone.0009432-Kang1], eluted peptide data from the SYFPEITHI [@pone.0009432-Rammensee1] database as well as RANKPEP [@pone.0009432-Reche1], SVMHC [@pone.0009432-Donnes1], and MHCPred tools [@pone.0009432-Gu1], [@pone.0009432-Parry1], which predicted the PspA peptides that bind HLA-DR, -DQ, and -DP alleles. To correlate these predictions with *in vivo* immunogenicity, PspA-specific HTL proliferation and cytokine responses were measured and correlated with predicted peptide-MHC binding affinities. A novel human isolate of capsular group 19 pneumococci, which was passed in mice to yield *S. pneumonia* strain EF3030, which has a greater propensity to cause nasal or pulmonary infections than sepsis when given intranasally, was used to accomplish this objective [@pone.0009432-Briles1]. Further, F1 (B6×Balb/c) mice have reduced susceptibility to *S. pneumonia* strain EF3030 and express functional I-A^b^, I-A^d^, I-E^b^, and I-E^d^. After these mice were nasally challenged with *S. pneumonia* strain EF3030, CLN- and spleen-derived CD4^+^ T cells were isolated and *ex vivo* stimulated with PspA peptides. Together, these *in silico* and *in vivo* methods revealed immunodominant PspA HTL epitopes that might serve as vaccine antigens.

Results {#s2}
=======

Peptide Selection, Binding Analysis, and Overview of PspA Predicted Secondary Structure {#s2a}
---------------------------------------------------------------------------------------

The aligned PspA amino acid sequence using 24 unrelated *S. pneumonia* strains, was previously shown to contain helical and charged immunogenic domains (i.e., Regions A, A\*, B, and C) [@pone.0009432-Hollingshead1]. As reported previously, the secretion signal peptide for PspA extends into the first 50 amino acids and has \>50% amino acid identity among strains. Region A encodes the first 100 amino acids (∼300 nucleotides) of PspA, beginning with the first amino acid of the mature protein. PspA is less conserved over the second half of Region A, where sequences begin to diverge and fall into groups. The amino terminal end of Region A\* is hypervariable, but the C-terminal end of Region A\* and much of Region B are more conserved among strains. Region C is proline-rich.

We created individual, yet overlapping peptides, that were 15 amino acids in length ([Table 1](#pone-0009432-t001){ref-type="table"}). The entire sequence of PspA was used to predict the protein structure as well as β turn (t) using PSIPRED (<http://bioinf.cs.ucl.ac.uk/psipred/>) [@pone.0009432-McGuffin1] and COUDES (<http://bioserv.rpbs.jussieu.fr/Coudes/index.html>) [@pone.0009432-Fuchs1] methods. Coiled--coiled (C) as well as helical (H) structures were noted throughout PspA ([Figure 1](#pone-0009432-g001){ref-type="fig"}). There were no β turns or potential asparagine (N) endopeptidase sites in Regions A or A\*.The majority of Region B is coiled with small helix (PspA~242--246~) and strand (PspA~286--293~) domains. In contrast, Region C displays an array of complex secondary structures as well as numerous potential N endopeptidase sites. The latter sites are typically found in bacterial cell wall-associated domains and known to enhance antigen-processing for MHC presentation [@pone.0009432-Manoury1].

![Modular PspA amino acid sequence showing regions of predicted immunogenicity and secondary structure.\
Major domains of PspA are indicated. The aligned amino acid sequence shows the previously defined PspA windows A, A\*, B and C. The PspA amino acid (AA) sequence was used to predict helical (H), coiled (C), α strand (E), β turns (t), and asparagine endopeptidase sites (N).](pone.0009432.g001){#pone-0009432-g001}
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###### Overlapping PspA peptides and antigenic region description.

![](pone.0009432.t001){#pone-0009432-t001-1}

  Peptide               Antigenic epitope region        Peptide         Antigenic epitope region
  -------------------- -------------------------- -------------------- --------------------------
  01-MNKKKMILTSLASVA             Leader            28-TIAAKKAELEKTEAD           Region B
  02-ASVAILGAGFVASQP             Leader            29-TEADLKKAVNEPEKP           Region B
  03-ASQPTVVRAEESPVA        Leader/Region A        30-PEKPAPAPETPAPEA          Region B/C
  04-SPVASQSKAEKDYDA            Region A           31-APEAPAEQPKPAPAP           Region C
  05-DYDAAKKDAKNAKKA            Region A           32-APAPQPAPAPKPEKP           Region C
  06-AKKAVEDAQKALDDA            Region A           33-PEKPAEQPKPEKTDD           Region C
  07-LDDAKAAQKKYDEDQ            Region A           34-KTDDQQAEEDYARRS           Region C
  08-DEDQKKTEEKAALEK            Region A           35-ARRSEEEYNRLTQQQ           Region C
  09-ALEKAASEEMDKAVA            Region A           36-TQQQPPKAEKPAPAP           Region C
  10-KAVAAVQQAYLAYQQ            Region A           37-APAPKTGWKQENGMW           Region C
  11-AYQQATDKAAKDAAD            Region A           38-NGMWYFYNTDGSMAT           Region C
  12-DAADKMIDEAKKREE           Region A\*          39-SMATGWLQNNGSWYY           Region C
  13-KREEEAKTKFNTVRA           Region A\*          40-SWYYLNSNGAMATGW           Region C
  14-TVRAMVVPEPEQLAE           Region A\*          41-ATGWLQYNGSWYYLN           Region C
  15-QLAETKKKSEEAKQK           Region A\*          42-YYLNANGAMATGWAK           Region C
  16-AKQKAPELTKKLEEA           Region A\*          43-GWAKVNGSWYYLNAN           Region C
  17-LEEAKAKLEEAEKKA           Region A\*          44-LNANGAMATGWLQYN           Region C
  18-EKKATEAKQKVDAEE           Region A\*          45-LQYNGSWYYLNANGA           Region C
  19-DAEEVAPQAKIAELE           Region A\*          46-ANGAMATGWAKVNGS           Region C
  20-AELENQVHRLEQELK           Region A\*          47-VNGSWYYLNANGAMA           Region C
  21-QELKEIDESESEDYA          Region A\*/B         48-GAMATGWLQYNGSWY           Region C
  22-EDYAKEGFRAPLQSK            Region B           49-GSWYYLNANGAMATG           Region C
  23-LQSKLDAKKAKLSKL            Region B           50-MATGWAKVNGSWYYL           Region C
  24-LSKLEELSDKIDELD            Region B           51-WYYLNANGAMATGWV           Region C
  25-DELDAEIAKLEDQLK            Region B           52-TGWVKDGDTWYYLEA           Region C
  26-DQLKAAEENNNVEDY            Region B           53-YLEASGAMKASQWFK           Region C
  27-VEDYFKEGLEKTIAA            Region B           54-QWFKVSDKWYYVNGL           Region C

Individual, yet overlapping, *Streptococcus pneumonia* strain R6 PspA peptides, 15 amino acids in length were used in *ex vivo* and *in silico* assays. The antigenic epitope regions based on homologous alignment of PspA amino acid sequences from other strains were previously described as leader, A, A\*, B, and C regions [@pone.0009432-Hollingshead1].

Next, the PspA peptide dataset was was used to determine MHC II binding affinities ([Table 2](#pone-0009432-t002){ref-type="table"}). These data span a total of 16 human and 4 mouse MHC class II types. IEDB, MHCPred, RANKPEP, SVMHC and SYFPEITHI MHC class II epitope databases scanned the entire sequence of PspA. In brief, PspA peptides were compared with archived peptide datasets of previously measured peptide-MHC class II affinities. Peptides were classified into binders (IC~50~\<500 nM) and non-binders (IC~50~≥500 nM) based on *in silico*-derived binding affinities. This analysis revealed that nearly all PspA peptides could potentially bind a variety of mouse and human MHC class II molecules. Finally, the amino acid sequence comprising PspA peptides 19 to 22 (or PspA~199--246~) was aligned with sequences from nearly 100 clinically relevant family 1 *S. pneumonia* strains ([Table 3](#pone-0009432-t003){ref-type="table"}). PspA~199--246~ is highly conserved among *S. pneumonia* strains and contains the C-terminal end of Region A\* and the beginning of Region B [@pone.0009432-Hollingshead1].

10.1371/journal.pone.0009432.t002

###### Overview of PspA peptide predicted binding affinities to MHC class II alleles.

![](pone.0009432.t002){#pone-0009432-t002-2}

  PspA Peptide Number    IC~50~ *in silico* prediction (nM)                    
  --------------------- ------------------------------------ ----- ----- ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  01                                    312                   177   --    --    1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0301, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0802, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, 4[\*](#nt102){ref-type="table-fn"}0101, 5[\*](#nt102){ref-type="table-fn"}0101
  02                                    316                   81    --    372                                                                                                                                     1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1501,DP4, DPw4, DQ1, DQ5
  03                                    171                   21    358   --                                                                                                                            1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0301, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}0701, 5[\*](#nt102){ref-type="table-fn"}0101
  04                                     71                   302   --    --                                                                                                                                                                                   1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, DP4, DP9
  05                                     --                   --    --    --                                                                                                                                             1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0802, 5[\*](#nt102){ref-type="table-fn"}0101, DQ5
  06                                    167                   56    --    --                                                                                                                                                                                1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, DP9, DQ1, DQ5
  07                                    338                   --    --    --                                                                                                                                                                                     1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, DQ8
  08                                    118                   17    --    --                                                                                                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701
  09                                    219                   57    499   --                                                                                                                                                                                  1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, DP4, DPw4,
  10                                    193                   12    --    337                                                                                                                                                         1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0701, 4[\*](#nt102){ref-type="table-fn"}0101, DQ1, DQ2, DQ5, DQ7
  11                                    223                   215   --    --                                                                                                                                              1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 3[\*](#nt102){ref-type="table-fn"}0101, DQ8
  12                                    380                   488   --    --                                                                                                                                                                 1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0301, 1[\*](#nt102){ref-type="table-fn"}0701, 5[\*](#nt102){ref-type="table-fn"}0101, DQ2
  13                                    241                   --    348   --                                                                                                                                      1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0802, 5[\*](#nt102){ref-type="table-fn"}0101, DP9, DPw4, DQ7, DQ8
  14                                    210                   34    --    --                                                                                                                                                1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0405, 5[\*](#nt102){ref-type="table-fn"}0101
  15                                    354                   46    --    --                                                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 5[\*](#nt102){ref-type="table-fn"}0101, DP9 , DQ1, DQ2
  16                                    182                   99    --    344                                                                                                                                                                                  1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DP9 , DQ7
  17                                     49                   --    --    --                                                                                                                                                                                   1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DP9, DQ2
  18                                    208                   12    --    307                                                                                                                                                                 1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, DQ8
  19                                    205                   104   --    --                                                                                                                                                                                      1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DQ2
  20                                    485                   --    493   --                                                                                                                                                          1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0301,1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DP4, DP9, DPw4, DQ1
  21                                    180                   --    --    --                                                                                                                                                                                                                                1[\*](#nt102){ref-type="table-fn"}0101
  22                                    121                   42    --    --                                                                                                                                                                               1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701,DP4, DP9, DQ1, DQ5
  23                                    452                   --    412   --                                                                                                   1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0802, 1[\*](#nt102){ref-type="table-fn"}0901, 5[\*](#nt102){ref-type="table-fn"}0101,DP4, DP9
  24                                    374                   --    --    --                                                                                                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701,
  25                                    365                   461   --    --                                                                                                                                                                                   1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DP9, DQ2
  26                                    462                    6    --    --                                                                                                                                              1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0405,1[\*](#nt102){ref-type="table-fn"}0701, 5[\*](#nt102){ref-type="table-fn"}0101, DQ2
  27                                    249                   112   --    --                                                                                                                     1[\*](#nt102){ref-type="table-fn"}0101,1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 5[\*](#nt102){ref-type="table-fn"}0101,DP4, DP9, DQ5
  28                                    124                   190   --    --                                                                                                                                                                                 1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DP9, DQ7, DQ8
  29                                     97                   10    411   --                                                                                                                                              1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 5[\*](#nt102){ref-type="table-fn"}0101, DQ5
  30                                     99                   125   --    --                                                                                                                                                                                      1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DQ2
  31                                    173                   57    --    --                                                                                                                                                                                      1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DQ2
  32                                    350                   15    --    --                                                                                                                                                                                      1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DQ2
  33                                    239                   --    --    --                                                                                                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701,
  34                                    349                   28    --    --                                                                                                                                                                                      1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DQ1
  35                                    457                   155   210   --                                                                                                                                                                                     1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DPw4
  36                                    211                   65    --    479                                                                                                                                                                                     1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701, DQ2
  37                                    369                   20    --    381                                                                                                                                                                                       1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0701,
  38                                    140                   105   --    378                                                                                                                                     1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1101, DQ1, DQ5, DQ7, DQ8
  39                                    204                   121   --    285                                                                                                                                               1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1302, 1[\*](#nt102){ref-type="table-fn"}1501
  40                                    348                   76    381   --                                       1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, 1[\*](#nt102){ref-type="table-fn"}1501, 5[\*](#nt102){ref-type="table-fn"}0101,DP4, DPw4
  41                                    264                   60    268   --                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101,1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1302, 1[\*](#nt102){ref-type="table-fn"}1501
  42                                    256                   175   --    357                                                                                1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, DQ8
  43                                    329                   21    --    --                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401,1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1501, 3[\*](#nt102){ref-type="table-fn"}0101, 5[\*](#nt102){ref-type="table-fn"}0101
  44                                    274                    7    --    --                                                                                                                         1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, DQ7
  45                                    485                   60    --    476                                                                                   1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 3[\*](#nt102){ref-type="table-fn"}0101, 5[\*](#nt102){ref-type="table-fn"}0101
  46                                     --                   44    --    --                                                                                                                                                1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1101
  47                                    255                   21    --    --                                            1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, 3[\*](#nt102){ref-type="table-fn"}0101, 5[\*](#nt102){ref-type="table-fn"}0101
  48                                    264                   47    --    --                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101,1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1302, 1[\*](#nt102){ref-type="table-fn"}1501
  49                                    255                   120   --    --                                                                1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, 5[\*](#nt102){ref-type="table-fn"}0101
  50                                    329                   --    --    --                                                                                                                                               1[\*](#nt102){ref-type="table-fn"}0101, , 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1501
  51                                    255                   45    --    --                                                           1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0404, 1[\*](#nt102){ref-type="table-fn"}0405, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 1[\*](#nt102){ref-type="table-fn"}1101, 1[\*](#nt102){ref-type="table-fn"}1302, 5[\*](#nt102){ref-type="table-fn"}0101,DP4, DQ5
  52                                    392                   204   --    --                                                                                                                                                 1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0301,1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}1501,1[\*](#nt102){ref-type="table-fn"}0701
  53                                     80                   27    --    --                                                                                                                                        1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}0901, 5[\*](#nt102){ref-type="table-fn"}0101,DP4, DPw4, DQ5
  54                                    387                   234   --    170                                                                                                                                            1[\*](#nt102){ref-type="table-fn"}0101, 1[\*](#nt102){ref-type="table-fn"}0401, 1[\*](#nt102){ref-type="table-fn"}0701, 1[\*](#nt102){ref-type="table-fn"}1501, 3[\*](#nt102){ref-type="table-fn"}0101, DQ8

\*Dashes (--) represent the predicted affinity of peptides that poorly (i.e., IC~50~\>500 nM) bind mouse I-A^b^, I-E^b^, I-A^d^, or I-E^d^ alleles. Similarly, absent HLA alleles are those that poorly (i.e., IC~50~\>500 nM) bind the corresponding peptide.

10.1371/journal.pone.0009432.t003

###### Alignment of PspA~199--256~ amino acid sequences from family 1 Pneumococci strains.

![](pone.0009432.t003){#pone-0009432-t003-3}

  Strain                                                                                                                                                                                                                                                                                                                                                                            NCBI Accession Number                                                                                                                              [\*](#nt103){ref-type="table-fn"}Conserved amino acid sequence
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  D39/R6                                                                                                                                                                                                                                                                                                                                                                                  NP_357715                                                                                                                                           DAEEVAPQAKIAELENQVHRLEQELKEIDESESEDYAKEGFRAPLQSK
  WU2                                                                                                                                                                                                                                                                                                                                                                                     AAF27710                                                                                                                                              EVAPQAKIAELENQVHRLEQELKEIDESESEDYAKEGFRAPLQSK
  195                                                                                                                                                                                                                                                                                                                                                                                     AAF68105                                                                                                                                              EEVAPQAKIAELENQVHRLEQELKEIDESDSEDYIKEGFRAPLQSE
  SP19                                                                                                                                                                                                                                                                                                                                                                                    AAF68093                                                                                                                                             AEEVAPQAKIAELENQVHKLEQKLKEIDESDSEDYVKEGFRAPLQSE
  CGSP14, R41                                                                                                                                                                                                                                                                                                                                                                      YP_001834837, ABY67182                                                                                                                                        EVAPQAKIAELENQVHRLEQDLKDINESDSEDYVKEGLRAPLQSE
  RHG79, OVP-41721                                                                                                                                                                                                                                                                                                                                                                   ABY67197, ACR50702                                                                                                                                       HAEEVAPQVKIAELENQVHKLEQKLKEIDESDSEDYVKEGLRAPLQSE
  EF3030                                                                                                                                                                                                                                                                                                                                                                              to be determined                                                                                                                                        .. EVALQAKIAELENQVHRLETELKEIDESDSEDYVKEGLRVPLQSE
  c2, OVP-43533, OVP-42723, OVP-43431, R24729, DBL5, HUB-6893, St 371/00                                                                                                                                                                                                                                                                               ACM45238, ACR50689, ACR50693, ACR50694, ABY67184, AAF27706, ACR50678, ABR53733                                                                                                         HAKEVAPQAKIAELENQVHRLEQDLKDINESDSEDYVKEGLRAPLQSE
  L81905, RH5, BG9739, MC-247                                                                                                                                                                                                                                                                                                                                              AAF27705, ABV60383, AAF27700, ACR50682                                                                                                                             RAKEVVLQAKIAELENEVHKLEQKLKEIDESDSEDYVKEGFRAPLQSE
  70585                                                                                                                                                                                                                                                                                                                                                                                 YP_002739507                                                                                                                                          RAKEVALQAKIAELENEVHRLETKLKEIDESDSEDYVKEGLRAPLQSE
  AC94                                                                                                                                                                                                                                                                                                                                                                                    AAF27698                                                                                                                                            RAKEVALQAKIAELENEVHRLETELKEIDESDSEDYVKEGLRVPLQSE
  SP6-BS73, EF6796, BG9163, RHG63                                                                                                                                                                                                                                                                                                                                         ZP_01819322, AAF27709, AAF27711, ABY67195                                                                                                                              EVALQAKIAELEYEVQRLEKELEEINESDSEDYAKEGFRAPLQSK
  SP18-BS74                                                                                                                                                                                                                                                                                                                                                                              ZP_01829602                                                                                                                                          HAEEVVPQAKIAELENEVQKLEKDLKEIDESDSEDYVKEGLRAPLQSE
  SP200, MC-332, SP221                                                                                                                                                                                                                                                                                                                                                          AAF67354, ACR50683, AAF68099                                                                                                                                  RAKEVALQAKIAELENQVHRLETELKEIDESDSEDYVKEGLRVPLQSE
  BG8838, R30318                                                                                                                                                                                                                                                                                                                                                                     AAF27703, ABW07806                                                                                                                                       HAEEVVPQAKIAELENEVQKLEKDLKEIDESDSEDYVKEGLRAPLQSE
  R30397, R171, BG6692                                                                                                                                                                                                                                                                                                                                                          ABV60382, ACH72677, AAF27704                                                                                                                                  HAEEVVPQAKIAELENEVQKLEKDLKEIDESDSEDYVKEGLRAPLQSE
  HUB-7682                                                                                                                                                                                                                                                                                                                                                                                ACR50697                                                                                                                                            RAKEVALQAKIAELENEVHRLETKLKEIDESDSEDYVKEGLRAPLQSE
  130                                                                                                                                                                                                                                                                                                                                                                                     AAF68103                                                                                                                                            HAEEVVPQAKIAELENEVQKLEKDLKEIDESASEDYVKEGLRAPLQSE
  R30318                                                                                                                                                                                                                                                                                                                                                                                  ABW07807                                                                                                                                            RAKEVALQAKIAELENEVHRLETKLKETDESDSEDYVKEGLRAPLQSE
  OVI-2328                                                                                                                                                                                                                                                                                                                                                                                ACR50701                                                                                                                                            HAKEVVPQAKIAELENEVQKLEKDLKEIDESDSEDYVKEGLRAPLQSE
  [\*](#nt103){ref-type="table-fn"}CDC1873-00, ST858, [\*](#nt103){ref-type="table-fn"}SP6-BS73, [\*](#nt103){ref-type="table-fn"}EF6796, ST860, [\*](#nt103){ref-type="table-fn"}SRF10, SP23-BS72, [\*](#nt103){ref-type="table-fn"}g5, E134, BG9163    ZP_02709307[†](#nt104){ref-type="table-fn"}, ABN71686, ZP_01820249[†](#nt104){ref-type="table-fn"}, AAD00184[†](#nt104){ref-type="table-fn"}, ABN71687, AAF73809[†](#nt104){ref-type="table-fn"}, ZP_01835080, AAF73801[†](#nt104){ref-type="table-fn"}, AAF13457, AAF13460          DAEEYALEAKIAELEYEVQRLEKELKEIDESDSEDYLKEGLRAPLQSK
  232                                                                                                                                                                                                                                                                                                                                                                                     AAF68104                                                                                                                                            HAEEVVPQAKIAELENEVQKLEKDLKEIDESASEDYVKEGLRAPLQSE
  P1031, R30087                                                                                                                                                                                                                                                                                                                                                                    YP_002737416, ABY67187                                                                                                                                     RAKEVALQAKIAELENEVHRLETKLKETDESDSEDYVKEGLRAPLQSE
  CDC3059-06                                                                                                                                                                                                                                                                                                                                                                             ZP_02717970                                                                                                                                          HAEEVAPQAKIAELEHEVQKLEKALKEIGESDSEDYVKEGLRAPLQSE
  OVP-42725                                                                                                                                                                                                                                                                                                                                                                               ACR50703                                                                                                                                                LFLQAKIAELENEVHKLEQKLKEIDESDSEDYVKEGFRAPLQSE
  PN124                                                                                                                                                                                                                                                                                                                                                                                   AAN37735                                                                                                                                                  AKIAELENQVHRLEQDLKDINESDSEDYVKEGFRAPLQSE
  DBL6A                                                                                                                                                                                                                                                                                                                                                                                   AAF27701                                                                                                                                            RAKEVVLQAQIAELENEVHKLEPKLKEIDESDSEDYVKEGFRAPLQSE
  St 435/96                                                                                                                                                                                                                                                                                                                                                                               AAL92492                                                                                                                                            HAEEVAPQAKIAELEHEVQKLEKALKEIDESDSEDYVKEGLRAPLQFE
  EF10197                                                                                                                                                                                                                                                                                                                                                                                 AAF27708                                                                                                                                            RAKEVVLHAKLAELENEVHKLDQKLKEIDESDSEDYVKEGFRAPLQSE
  R402                                                                                                                                                                                                                                                                                                                                                                                    ABY67181                                                                                                                                            HAEEVAPQAKIAELEHEVQKLEKALKEIDESDSEDYVKEGLRAPLQFE
  DBL1                                                                                                                                                                                                                                                                                                                                                                                    AAF27702                                                                                                                                            RAKEVALQAKIAELENEVYRLETELKGIDESDSEDYVKEGLRAPLQSE
  HUB-4197, 237                                                                                                                                                                                                                                                                                                                                                                      ACR50680, AAF68102                                                                                                                                       HAEEVAPQAKIAELEHEVQKLEKALKEIDESDSEDYVKEGLRAPLQFE
  c1, SP194, RHG95, HUB-2371, PC4, RH21, RH12                                                                                                                                                                                                                                                                                                               ACM45237, AAF68092, ABV60384, ACR50685, ABV30914, ABY67192, ABW07810                                                                                                              RAKEVALQAKIAELENEVYRLETELKGIDESDSEDYVKEGLRAPLQSE
  SP23-BS72, SP196, URSP2, 233, 152, 164, BG8743, 183, HUB-6892, 90, 177, 137, 39, RH9                                                                                                                                                                                                                                  ZP_01834257, AAF67355, AAR20918, AAF70097, AAF70096, AAF70094, AAF27699, AAF70095, ACR50684, AAF70093, AAF70091, AAF70090, AAF70092, ABW07809                                                                            KYALEAKIAELEYEVQGLEKELKEIDESDSEDYIKEGLRAPLQSK
  R23661, R30360, OVP-40742                                                                                                                                                                                                                                                                                                                                                          ABV30913, ABY67189,                                                                                                                                         KYALEAKIAELEYEVQRLEKEIKEIDESDSEDYLKEGLRAPLQSE
  R11561                                                                                                                                                                                                                                                                                                                                                                                  ACH72679                                                                                                                                             EVAPQAKIAELENQVHRLEQDL\-\-\-\--SDSEGYVKEGLRAPLQSE
  E134                                                                                                                                                                                                                                                                                                                                                                                    AAF27707                                                                                                                                               KYALEAKISELEYEVQGLGKELKEIDESDSEDYXKEGLRAPLQSK
  SP356                                                                                                                                                                                                                                                                                                                                                                                   AAN37734                                                                                                                                                   IAELENEVYRLETELKGIDESDSEDYVKEGLRAPLQSE
  R83                                                                                                                                                                                                                                                                                                                                                                                     ACH72676                                                                                                                                              KYALEAKIAELEYEVQRVEKEIK\--DESDSEDYLKEGLRAPLQSE
  P105                                                                                                                                                                                                                                                                                                                                                                                    ABE67219                                                                                                                                                         LEKEIKEIDESDSEDYLKEGLRAPLQSE
  P755, P13                                                                                                                                                                                                                                                                                                                                                                          ABE67236, ABE67218                                                                                                                                                      LKEIDESDSEDYVKEGFRAPLQSE
  P1151                                                                                                                                                                                                                                                                                                                                                                                   ABE67224                                                                                                                                                           LKEIDESDSEDYIKEGVRAPLQSK
  P308                                                                                                                                                                                                                                                                                                                                                                                    ABE67222                                                                                                                                                           LKEIDESDSEDYIKEGLRAPLQSK
  P176, 371/00, P1161                                                                                                                                                                                                                                                                                                                                                           ABE67232, AAL92493, ABE67225                                                                                                                                                 LKEIDESDSEDYVKEGLRAPLQSE

\*Alignment of conserved *Streptococcus pneumonia* PspA~199--256~ amino acid sequences appear as white text in black boxes.

†NCBI accession number of PspC that align with PspA~199--246~.

PspA Peptide-Specific Systemic and Mucosal CD4^+^ T Cell Proliferation Responses {#s2b}
--------------------------------------------------------------------------------

To better determine whether predicted PspA peptide-MHC class II binding affinities corresponded with HTL proliferation, PspA peptide-specific CD4^+^ T cell responses were characterized 28 days after *S. pneumoniae* strain EF3030 or mock (naïve) challenge. PspA peptide-specific proliferative responses by naïve CD4^+^ T cells were relatively low ([Figure 2](#pone-0009432-g002){ref-type="fig"}). However, spleen- or CLN-derived CD4^+^ T cell from *S. pneumonia* strain EF3030-challenged mice showed selective yet significant proliferation indexes to PspA peptides. Spleen-derived HTLs from *S. pneumonia* strain EF3030-challenged mice significantly proliferated in response to PspA peptides 21, 22, and 23 than compared to naïve controls. CLN CD4^+^ T cell PspA peptide-specific proliferation responses were moderately higher than similar cells isolated from the spleen of *S. pneumonia* strain EF3030-challenged mice, with comparatively higher responses to PspA peptides 21 and 23.

![Proliferation responses of PspA peptide-specific systemic and mucosal CD4^+^ T cells during pneumococcal carriage.\
Spleen and cervical lymph node (CLN) lymphocytes were isolated from F1 (B6×Balb/c) mice, 28 days after intranasal challenge with *Streptococcus pneumonia* strain EF3030 (▪) and naïve (□). CD4^+^ T cells were incubated with 1 µM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naïve syngeneic feeder cells, for 3 days, at a ratio of 5∶1×10^6^ cells. Proliferation was measured by BrdU incorporation, which was measured by ELISA. The data presented are the mean OD~450~. Experimental groups consisted of 10 mice. The results were expressed as the mean ± the standard error mean (SEM) of the response from 3 replicate determinations of three independent experiments.](pone.0009432.g002){#pone-0009432-g002}

PspA Peptide-Specific T Helper Cytokine Profiles {#s2c}
------------------------------------------------

In general, pneumococcal infection resulted in significantly higher HTL cytokine secretion by *ex vivo* PspA peptide-stimulated CD4^+^ T cells from the spleen as well as CLNs of *S. pneumonia* strain EF3030-challenged mice, than compared to naïve mice ([Figures 3](#pone-0009432-g003){ref-type="fig"} and [4](#pone-0009432-g004){ref-type="fig"}). In contrast to proliferation responses, spleen-derived CD4^+^ T cells from *S. pneumonia* strain EF3030-challenged mice secreted higher levels of IFN-γ and IL-2 after PspA peptide *ex vivo* stimulation than did similar cells from CLNs. HTLs from CLNs of pneumococcal-challenged mice, significantly responded to PspA peptides 20 and 21. CD4^+^ T cells isolated from the spleen and CLNs also significantly secreted Th2 cytokines after *ex vivo* stimulation of PspA peptides, than compared to naïve mice.

![PspA peptide-specific IFN-γ secretion by CD4^+^ T cell following pneumococcal challenge.\
Groups of 10 F1 (B6×Balb/c) mice were intranasally challenged with 10^7^ CFUs of *S. pneumonia* strain EF3030 in a 15 µl volume of Ringer\'s solution. Spleen and cervical lymph node (CLN) lymphocytes were isolated from mice, 28 days after intranasal challenge with *Streptococcus pneumonia* strain EF3030 (▪) and naïve (□). CD4^+^ T cells were incubated with 1 µM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naïve syngeneic feeder cells, for 3 days, at a ratio of 5∶1×10^6^ cells. The results were expressed as the mean ± the standard error mean (SEM) of IFN-γ supernatant levels from 3 replicate determinations of three independent experiments. IFN-γ production of cultured supernatants was determined by Luminex capable of detecting \>2 pg/ml of IFN-γ.](pone.0009432.g003){#pone-0009432-g003}

![PspA peptide-specific IL-2 secretion by CD4^+^ T cell following pneumococcal challenge.\
Groups of 10 F1 (B6×Balb/c) mice were intranasally challenged with 10^7^CFUs of *S. pneumonia* strain EF3030 in a 15 µl volume of Ringer\'s solution. Spleen and Cervical lymph node (CLN) lymphocytes were isolated from mice, 28 days after intranasal challenge with *Streptococcus pneumoniae* strain EF3030 (▪) and naïve (□). CD4^+^ T cells were incubated with 1 µM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naïve syngeneic feeder cells, for 3 days, at a ratio of 5∶1×10^6^ cells. The results were expressed as the mean ± the standard error mean (SEM) of IL-2 supernatant levels from 3 replicate determinations of three independent experiments. IL-2 production of cultured supernatants was determined by Luminex capable of detecting \>2 pg/ml of IL-2.](pone.0009432.g004){#pone-0009432-g004}

Similar to proliferation responses, CLN CD4^+^ T cells from *S. pneumonia* strain EF3030-challenged mice significantly secreted IL-10 following PspA peptide restimulation, with comparatively higher responses to PspA peptides 19, 20, and 21. Splenic HTLs selectively secreted significant levels of IL-10 in response to PspA peptides 13, 19, and 21 than compared to naïve mice ([Figure 5](#pone-0009432-g005){ref-type="fig"}). While cells from naïve mice did not significantly respond to PspA peptides, CD4^+^ T lymphocytes from *S. pneumonia* strain EF3030-challenged mice also significantly secreted IL-4 and IL-5 after PspA peptide *ex vivo* stimulation ([Figures 6](#pone-0009432-g006){ref-type="fig"} and [7](#pone-0009432-g007){ref-type="fig"}). In particular, there were comparatively higher responses to PspA peptides 19, 20, and 21 by splenic HTLs. Similar CLN Th2 cells secreted IL-4 in response to peptides 19 and 20 whereas heightened IL-5 secretion was noted in response to peptides 19 to 22 as well as 29 and 35, than compared to naive mice.

![PspA peptide-specific IL-10 secretion by CD4^+^ T cell following pneumococcal challenge.\
Groups of 10 F1 (B6×Balb/c) mice were intranasally challenged with 10^7^CFUs of *S. pneumonia* strain EF3030 in a 15 µl volume of Ringer\'s solution. Spleen and Cervical lymph node (CLN) lymphocytes were isolated from mice, 28 days after intranasal challenge with *Streptococcus pneumonia* strain EF3030 (▪) and naïve (□). CD4^+^ T cells were incubated with 1 µM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naïve syngeneic feeder cells, for 3 days, at a ratio of 5∶1×10^6^ cells. The results were expressed as the mean ± the standard error mean (SEM) of IL-10 supernatant levels from 3 replicate determinations of three independent experiments. IL-10 production of cultured supernatants was determined by Luminex capable of detecting \>2 pg/ml of IL-10.](pone.0009432.g005){#pone-0009432-g005}

![PspA peptide-specific IL-4 secretion by CD4^+^ T cell following pneumococcal challenge.\
Groups of 10 F1 (B6×Balb/c) mice were intranasally challenged with 10^7^CFUs of *S. pneumonia* strain EF3030 in a 15 µl volume of Ringer\'s solution. Spleen and Cervical lymph node (CLN) lymphocytes were isolated from mice, 28 days after intranasal challenge with *Streptococcus pneumonia* strain EF3030 (▪) and naïve (□). CD4^+^ T cells were incubated with 1 µM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naïve syngeneic feeder cells, for 3 days, at a ratio of 5∶1×10^6^ cells. The results were expressed as the mean ± the standard error mean (SEM) of IL-4 supernatant levels from 3 replicate determinations of three independent experiments. IL-4 production of cultured supernatants was determined by Luminex capable of detecting \>2 pg/ml of IL-4.](pone.0009432.g006){#pone-0009432-g006}

![PspA peptide-specific IL-5 secretion by CD4^+^ T cell following pneumococcal challenge.\
Groups of 10 F1 (B6×Balb/c) mice were intranasally challenged with 10^7^CFUs of *S. pneumonia* strain EF3030 in a 15 µl volume of Ringer\'s solution. Spleen and Cervical lymph node (CLN) lymphocytes were isolated from mice, 28 days after intranasal challenge with *Streptococcus pneumonia* strain EF3030 (▪) and naïve (□). CD4^+^ T cells were incubated with 1 µM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naïve syngeneic feeder cells, for 3 days, at a ratio of 5∶1×10^6^ cells. The results were expressed as the mean ± the standard error mean (SEM) of IL-5 supernatant levels from 3 replicate determinations of three independent experiments. IL-5 production of cultured supernatants was determined by Luminex capable of detecting \>2 pg/ml of IL-5.](pone.0009432.g007){#pone-0009432-g007}

In summary, CD4^+^ T cells from *S. pneumonia* strain EF3030-challenged mice consistently mounted significant yet select proliferation and IL-10 responses (CLN\>\>spleen), IFN-γ, IL-2 and IL-4 secretion (spleen\>\>CLN) and IL-5 expression (spleen≤CLN) largely in response to PspA peptides 19, 20, 21, and 22. Moreover, PspA peptides 21 and 22 mounted comparatively high proliferation responses, 20 and 21 induced consistently high IFN-γ and IL-2 responses, and 19, 20, and 21 caused IL-10, IL-4 and IL-5 responses by HTLs isolated from Pneumococci-exposed mice.

Predicted PspA Peptide-MHC Class II Alleles Binding Affinities and Correlation with Proliferation and Cytokine Secretion Responses {#s2d}
----------------------------------------------------------------------------------------------------------------------------------

PspA peptides 19, 20, 21, and 22 mounted significant HTL responses, and displayed strong predictive binding affinities to numerous HLA-DR, -DQ, and -DP as well as I-A^b^ and I-E^d^ haplotypes. This is best illustrated by viewing a 3-dimensional plot of the proliferation index as well as IFN-γ, IL-10, IL-2, IL-4, and/or IL-5 responses compared with MHC allele binding affinities ([Figures 8](#pone-0009432-g008){ref-type="fig"} and [9](#pone-0009432-g009){ref-type="fig"}). PspA peptide-specific T cell proliferation and IFN-γ, IL-10, IL-2, IL-4 and IL-5 secretion by CLN and splenic CD4^+^ T cells from *S. pneumonia* strain EF3030-challenged mice was higher than the naïve group. In general, CLN HTLs from mice previously challenged with *S. pneumonia* strain EF3030) secreted high levels of IFN-γ, IL-2, IL-4, IL-5 and IL-10 as well as enhanced proliferation in response to PspA peptides (19, 20\>21, 22) stimulation.

![3D plot of Th1/Th2 cytokine secretion relative to proliferation or I-A/I-E predicted peptide-binding by cervical lymph node-derived CD4^+^ T cells.\
The panels summarize IFN-**γ**, IL-10, IL-2, IL-4, IL-5 and proliferation responses of PspA peptide-specific CD4^+^ T cells isolated from cervical lymph nodes of F1 (B6×Balb/c) mice, 28 days after *S. pneumonia* strain EF3030- challenge and predicted I-A or I-E binding affinities. Y-axis and X-axis indicate the concentration (ng/ml) of IFN-γ and IL-10, IL-2, IL-4, IL-5 respectively, secreted by PspA peptide-stimulated CD4^+^ T cells. The Z- axis represents the predicted I-A or I-E binding affinities (Kd). PspA peptides 19, 20, 21 and 22 appear as white circles, while remaining peptides are open circles.](pone.0009432.g008){#pone-0009432-g008}

![3D plot of Th1/Th2 cytokine secretion relative to proliferation or I-A/I-E predicted peptide-binding by spleen- derived CD4^+^ T cells.\
The panels summarize IFN-**γ**, IL-10, IL-2, IL-4, IL-5 and proliferation responses of PspA peptide-specific CD4^+^ T cells isolated from spleen of F1 (B6×Balb/c) mice, 28 days after *S. pneumonia* strain EF3030-challenge and predicted I-A or I-E binding affinities. Y-axis and X-axis indicate the concentration (ng/ml) of IFN-γ and IL-10, IL-2, IL-4,IL-5 respectively, secreted by PspA peptide-stimulated CD4^+^ T cells. The Z-axis represents the predicted I-A or I-E binding affinities (Kd). PspA peptides 19, 20, 21 and 22 appear as white circles, while remaining peptides are open circles.](pone.0009432.g009){#pone-0009432-g009}

PspA peptides 19, 20, 21, and 22 were predicted to bind I-A^b^/I-A^d^, I-A^b^/I-E^b^, I-A^b^ and I-A^b^/I-A^d^, respectively, with IC~50~\<500 nM. From these, PspA peptide 20 was predicted to have marginal binding affinities to I-A^b^ and I-E^b^ with IC~50~ = 485 and 493 nM, respectively. This also corresponded with relatively high IL-10 responsiveness. Spleen-derived CD4^+^ T cells secreted significant amounts of IFN-γ, IL-2, IL-4 and IL-5 as well as proliferated in response to PspA peptides 19, 20, 21, and 22 (i.e., PspA~199--246~) stimulation from mice previously challenged with *S. pneumonia* strain EF3030. Peptide 20 or 23 stimulation of splenic HTLs resulted in comparatively high secretion of IL-10. Similar to PspA peptide 20, peptide 23 was predicted to have moderate I-A^b^ and I-E^b^ binding affinity i.e., IC~50~ = 452 and 412 nM, respectively. Peptides that induced spleen-derived CD4^+^ T cells to secrete high levels of Th1 (IFN-γ/IL-2) and Th2 (IL-4/IL-5) cytokines also correlated with relatively high MHC binding affinities. It is important to note that several PspA peptides predicted to tightly bind I-A and/or I-E alleles did not always correspond with elevated cytokine secretion (e.g., peptides 6, 18, 30, and 53).

Discussion {#s3}
==========

The immune system is remarkably robust in responding to a multitude of foreign antigens. T cells are crucial for generating an efficient immune response following recognition of foreign antigen in the context of MHC. The polymorphism of MHC genes leads to differences in immune responsiveness. While peptide vaccines potentially circumvent the problem of using whole antigen or attenuated pathogens as vaccines, this approach is impeded by the exhaustive MHC repertoire [@pone.0009432-Reche2]. Hence, the identification of optimal or common HTL epitopes is imperative in mounting a protective immune response. To this end, MHC α chains have limited variability compared to MHC β chains suggesting that the binding affinity of MHC β chains dictates antigenic specificity [@pone.0009432-Corte1], [@pone.0009432-Shackelford1]. This restricts the utility of peptides as vaccines. The discovery of "promiscuous" or "universal" peptides that can bind multiple HLA (β chain) allele would solve many of these problems. While HLA-transgenic mice have been used to map HTL epitopes [@pone.0009432-Yu1], the limited number of HLA transgenic mice are not representative of all populations. Hence, the current study is the first of many to map clinically relevant HTL pneumococcal epitopes. We have utilized *in silico* methods for predicting class II-restricted peptides and evaluated immunogenicity by *ex vivo* peptide-restimulation.

Protein secondary structure consists of regular elements such as α-helices and β-sheets, and irregular elements such as β-bulges, random coils, and tight turns. Tight turns are generally classified as δ-, γ-, β-, α-, and π-turns according to the number of residues involved [@pone.0009432-Chou1]. β-turns have important biological tasks [@pone.0009432-Kaur1]. We predicted β-turns in PspA using a new and highly accurate secondary structure prediction software, PSIPRED, which incorporates two feed forward neural networks that perform an analyses on PSI-BLAST position-specific-iterated- BLAST peptide sequence [@pone.0009432-Altschul1]. β-turns were abundant in PspA Region C, which did not have immunodominant HTL epitopes. While β-sheet structures were not detected, analysis revealed PspA has α-helical secondary structure content and is predominantly a coiled-coil structure. These structural properties correlate with PspA function and anti-complement activity [@pone.0009432-Jedrzejas1]. In general, PspA peptides with continuous helix or strand predicted secondary structures were not considered immunodominant; instead, PspA peptides 19, 20, 21, and 22 (or PspA~199--246~) were estimated to predominantely have a coiled secondary structure.

In addition to protein secondary structure, proteases and MHC class II co-mingle in the antigen-processing compartment and compete for peptides that satisfy requirements for protease or MHC recognition, respectively. Indeed, several proteases are implicated in processing antigen and the MHC class II-bound invariant chain [@pone.0009432-Riese1], [@pone.0009432-Pluger1], [@pone.0009432-Villadangos1]. The proteolytic separation of MHC class II-bound epitopes was found to be a rate-limiting step in the presentation of T cell epitopes [@pone.0009432-Castellino1]. The level and activity of N endopeptidases can directly control the proteolysis and presentation of T cell epitopes [@pone.0009432-Manoury2]. In contrast to other proteases, N endopeptidase is required for both antigen and invariant chain (Ii) processing [@pone.0009432-Chen1], [@pone.0009432-Chen2], [@pone.0009432-Blum1], [@pone.0009432-Amigorena1]. Hence, N endopeptidase can have both positive and negative effects on the outcome of antigen processing [@pone.0009432-Manoury1], [@pone.0009432-Antoniou1], [@pone.0009432-Watts1]. Future studies will be required to verify whether the candidate HTL peptides are able to induce protective immunity against to pneumococcal infection.

PspA is highly immunogenic and is considered a promising vaccine candidate for combating pneumococcal infection [@pone.0009432-McDaniel1], [@pone.0009432-Berry1], [@pone.0009432-Palaniappan1]. In our model, *S. pneumonia* strain EF3030 promoted substantial PspA peptide-specific HTL responses. We show that PspA~199--246~ (i.e., PspA peptides 19, 20, 21, and 22) is highly immunogenic and likely encompasses HLA class-binding epitopes to support pneumococcal immunity. Further, PspA ~199--246~ is highly conserved among 100 different family 1 *S. pneumonia* strains ([Table 3](#pone-0009432-t003){ref-type="table"}). In confirmation, Region B lies within PspA~199--246~ and was found to be important in eliciting protective pneumococcal immunity [@pone.0009432-McDaniel2]. Taken together, our findings support the rationale for additional studies to explore the utility of PspA~199--246~-based vaccines.

*S. pneumonia* has co-evolved with man and no doubt has numerous immune evasion mechanisms to avoid detection by T cells. From the pathogen\'s perspective, it would be critical to maintain PspA function, while reducing detection of a T cell immuno-dominant epitope (i.e., peptide 21). PspA peptide 21 restimulation of pneumococcal-infected mice induced significant cytokine production and proliferation, yet was predicted to be poorly recognized by mouse and human MHC class II alleles. In contrast, other immunodominant regions exist within peptides 38 to 41 and might be protective since they invoked CD4^+^ T cell proliferation as well as T helper cytokine responses. However, these peptides reside in Region C, which has several potential, N endopeptidase sites along with β turn secondary structures that would optimally expose these sites for cleavage. In particular, peptide 40 has a highly conserved N endopeptidase site (i.e., NxN) that lies in the middle of a pronounced β turn secondary structure (ttttt). While this intact peptide would potentially bind several MHC class II alleles, it is also likely that it would be cleaved before or after MHC-binding by N endopeptidases.

The Th1-associated cytokine, IL-2 promotes T cell proliferation. Our data show PspA~199--246~ peptides mounted comparatively high IL-2 and proliferation HTL recall responses in mice previously challenged with *S. pneumonia* strain EF3030. Another Th1 cytokine, IFN-γ, is required for protective pneumococcal immunity [@pone.0009432-Pomeroy1]. CD4^+^ T cells from *S. pneumonia* strain EF3030-challenged mice secreted significant amounts of IFN-γ following *ex vivo* PspA peptide re-stimulation. IFN-γ blockade accelerated the death of animals during pneumococcal infection [@pone.0009432-Weigent1], whereas treatment of mice with IFN-γ enhanced the survival of mice [@pone.0009432-Lynch1]. However, confounding studies suggest that too much IFN-γ and too little IL-10 can inhibit pneumococcal clearance during *S. pneumonia* infection that is secondary to influenza virus infection [@pone.0009432-Sun1].

IL-10 has been suggested to be both deleterious and important for pneumococcal immunity. On one hand, administration of anti-IL-10 antibody was shown to enhance pneumococcal immunity [@pone.0009432-Menahem1], while others showed this Th2-associated cytokine is critical for MARCO-1 expression and subsequent pneumococcal clearance [@pone.0009432-Sun1]. We show that PspA~199--246~ stimulates pneumococcal strain EF3030-primed CD4^+^ T cells to secrete IL-10. Interestingly, HTLs from CLN mounted IL-10 responses to more peptides, than similar cells isolated from the spleen. Perhaps this contributes to establishing pneumococcal carriage by supporting selective pneumococcal clearance by CLN\>\>spleen antigen-presenting cells after stimulation with CD4^+^ T cell-derived IL-10, whereas IFN-γ-secreting HTLs might support spleen\>\>CLN macrophages activation and/or internalization of *S. pneumonia*.

In the absence of IL-10, a marked increase in pro-inflammatory cytokines is induced during pneumococcal infection [@pone.0009432-Tsuchiya1]. To this end, IL-10 plays an indispensable role in mucous cell metaplasia and hyperplasia. IL-10 attenuates the proinflammatory cytokine response and its absence hampers effective clearance of the infection, and reduces survival of pneumococcal infection [@pone.0009432-vanderPoll1]. We have shown that CCL5 inhibition resulted in lower IFN-γ-secreting CD4^+^ T cells and significantly more PspA-specific IL-10-producing CD4^+^ T cells, which corresponded with the transition from pneumococcal carriage to lethal pneumonia [@pone.0009432-Palaniappan1], [@pone.0009432-Palaniappan2]. Thus, the precise contribution of IL-10 in pneumococcal immunity remains uncertain, but the preponderance of the evidence suggests excessive IL-10 responses play a deleterious role in pneumococcal immunity, but moderate levels of this cytokine are required for optimal adaptive (humoral) immune responses to *S. pneumonia* and reduced mucosal hyperplasia.

An effective intranasal conjugate pneumococcal vaccine using interleukin-12 (IL-12) as a mucosal adjuvant induced protection and increased expression of lung and splenic IFN-γ and IL-10 mRNAs and protected mice from lethal challenge [@pone.0009432-Khan1]. Thus, interplay and requirement of the HTL-derived IFN-γ and IL-10 in pneumococcal carriage and pneumonia will require further study. In addition, the adjuvants or cytokines, e.g., IL-12, required by antigen presenting cells to promote IFN-γ and IL-10 secreting, PspA-specific T cells will be addressed in the future.

Some studies suggest that Th2 cytokines do not support optimal pneumococcal immunity. Mice primed to mount Th2 cell responses followed by pneumococcal infection showed an increase in the number of Pneumococci and an increase in sinus inflammation than compared to naive or Th1 -primed groups [@pone.0009432-Yu2]. IL-4 plays a central role in directing the development of the Th2 phenotype and IL-4 responses in lung have been associated with an increased risk to pneumococcal infection [@pone.0009432-Kang2]. While IL-4 does not stimulate T cell proliferation, it induces the growth of lymphoblasts [@pone.0009432-Murtaugh1]. IL-5 was originally defined as a Th2 cell-derived cytokine that triggers B cell activation and differentiation into plasma cells [@pone.0009432-Kouro1]. PspA~199--249~-specific HTLs from *S. pneumonia* strain EF3030-challenged mice secreted significant amounts of IL-4 (spleen\>\>CLN) and IL-5 (spleen≤CLN) largely in response to PspA peptides 19, 20, 21, and 22. However, the uncertain role of IL-4 and IL-5 in pneumococcal cellular immunity makes correlations of these cytokines with protective immunity difficult.

The role of Th17 cells in pneumococcal immunity has not been extensively studied. However, recent reports suggest that IL-17A supports antibody responses to pneumococcal capsular polysaccharides [@pone.0009432-Malley1]. Mice lacking the IL-17A receptor or mice with neutrophil depletion are more susceptible to pneumococci [@pone.0009432-Lu1]. Additional studies on the role of HTL-derived IL-17 would greatly contribute to the field and will be required to understand how secretion of this cytokine correlates with pneumococcal immunity.

While the precise role of peptide MHC class II interactions that determine protective pneumococcal immunity are not known, this study addresses important questions that are relevant to MHC polymorphisms and antigen responsiveness. A number of studies have definitively proven a cause and effect relationship between human MHC genes and resistance to infection [@pone.0009432-FullerEspie1], [@pone.0009432-Mack1] as well as autoimmune diseases [@pone.0009432-Rosloniec1]. I-A, which is highly homologous to HLA-DQ [@pone.0009432-Bono1], typically restricts antigen-specific CD4^+^ T cells in mice, whereas I-E (homologous to HLA-DR) [@pone.0009432-Walker1], [@pone.0009432-Silver1], [@pone.0009432-Hurley1] has been reported to control non-responsiveness through antigen-specific suppressor cells [@pone.0009432-Ottenhoff1]. Further studies will be required to determine whether I-E or I-A as well as DQ or DR molecules might be involved in pneumococcal antigen non-responsiveness or cytokine secretion in mouse or man, respectively. To this end, many of the PspA peptides were predicted to bind I-A, while relatively few were predicted to bind I-E. These studies support the use of *in silico* and *in vivo* methods to validate T cell responsiveness to PspA peptide-based vaccines.

Materials and Methods {#s4}
=====================

Animals {#s4a}
-------

Female F1 (B6×Balb/c) mice, aged 8 to 12 weeks, contain MHC class II haplotype and corresponding TCR diversity that approaches those seen in man [@pone.0009432-Ridgway1], [@pone.0009432-Gregersen1] and were purchased from Jackson Laboratories. All mice were housed in horizontal laminar flow cabinets free of microbial pathogens. Routine antibody screening for a large panel of pathogens and routine histological analysis of organs and tissues were performed to insure that mice were pathogen free.

*S. pneumonia* Strain EF3030 Growth and Challenge {#s4b}
-------------------------------------------------

*S. pneumonia* capsular strain EF3030 was among the human isolates of capsular group 19 that were previously examined and found to be relatively non-invasive in mice [@pone.0009432-Briles2]. Pneumococci were grown in Todd Hewitt broth and stored frozen in aliquots at −80°C, in 20% glycerol, in sterile lactated Ringer\'s solution (Ringer\'s) (Abbott Labs, North Chicago, IL) [@pone.0009432-Aaberge1], [@pone.0009432-Briles3]. To establish nasal carriage, Pneumococci were introduced into groups of mice (8 to 12 week old) by nasal administration. The animals were anesthetized with ketamine (100 mg/ml) and xylazine (20 mg/ml), mixed at a 4∶1 (vol/vol) ratio. The anesthesia mixture was injected intramuscularly into the right hamstring muscle at a dose of 100 mg of ketamine per kg of body weight. After anesthesia was established, the mice were inoculated with approximately 10^7^ colony forming units (CFU) of *S. pneumonia* strain EF3030 in 15 µl of Ringer\'s solution using a 25-gauge ball-tipped gavage needle [@pone.0009432-Kadioglu1]. Experimental groups consisted of 10 mice and studies were repeated 3 times. The guidelines proposed by the committee for the Care of Laboratory Animal Resources Commission of Life Sciences - National Research Council were followed to minimize animal pain and distress. All procedures involving mice were approved by the Morehouse School of Medicine Committees (IACUC).

Pneumococcal Antigens {#s4c}
---------------------

54 overlapping peptides, spanning the entire length of *S. pneumonia* strain D39/R6 PspA protein sequence (NCBI Accession \# NP_357715), starting with the first 15 residues at the N- terminus, was synthesized by the multipin synthesis method by Chiron Mimotopes Peptide Systems. Peptides overlapped by four amino acids ([Table 1](#pone-0009432-t001){ref-type="table"}) and were acetylated at the N- terminus and ended with a COOH-terminal. Purity of these peptides was approximately 95%. The peptides were dissolved in a mixture (v/v) of 75% dimethyl sulfoxide and 25% water, to a concentration of 70 mM, divided into small aliquots and stored frozen at −80°C.

Tissue Collection and Cell Isolation {#s4d}
------------------------------------

Mice were sacrificed by CO~2~ inhalation to collect spleen and CLNs for single cell isolation of lymphocytes 28 days following *S. pneumonia* strain EF3030 challenge. Individual single cell suspensions of spleen and CLNs were collected and prepared by aseptically removing tissues and passage through a sterile wire screen. Unpooled CD4^+^ T cells were further separated by OctoMACS™ (Miltenyi Biotec) using negative selection. Remaining (non-CD4^+^) cells, were used as accessory feeder cells for antigen peptide-specific stimulation assays after mitomycin C (Sigma-Aldrich) treatment.

Cytokine Quantitation by Luminex™ Analysis {#s4e}
------------------------------------------

Purified CD4^+^ T cells and mitomycin C-treated feeder cells were cultured at a density of 5×10^6^ and 10^6^ cells per ml, respectively, in complete medium containing 1 µM of each PspA peptide at 37°C in 5% CO~2~. For the assessment of cytokine production, 100 µL of culture supernatants from 96-well flat bottom plates (Corning Glass Works) were harvested 3 days after *ex vivo* PspA peptide stimulation to determine the levels of IL-10 and IFN-γ secreted by CD4^+^ T cells. phorbol-12-myristate-13-acetate (PMA) 1 µg/ml was used as a positive control , ovalbumin (1 µg/ml) and medium only is used as negative control to reduce the background reading. Supernatant cytokine levels were determined by the Beadlyte™ mouse multi-cytokine detection (Bio-Rad). Briefly, filter bottom ELISA plates were rinsed with 100 µL of Bio-plex assay buffer and liquid was removed using a Millipore™ Multiscreen Separation Vacuum Manifold System set at 5 mm Hg. Analyte beads in assay buffer were added to the wells followed by 50 µL of serum or standard solution. The plates were incubated for 30 minutes at room temperature with continuous shaking (at setting \#3) using a Lab-Line™ Instrument Titer Plate Shaker. The filter bottom plates were washed, as before, and centrifuged at 300×g for 30 seconds. Subsequently, 50 µL of anti-mouse IL-10 or IFN-γ antibody-biotin reporter solution was added in each well, after which the plates were incubated with continuous shaking for 30 min followed by centrifugation and washing. Next, 50 µL streptavidin-phycoerythrin (PE) solution was added, and the plates were incubated with continuous shaking for 10 min at RT. 125 µL of Bio-plex assay buffer was added, and Beadlyte™ readings were measured using a Luminex™ System and calculated using Bio-plex™ software (Bio-Rad). The cytokine Beadlyte™ assays were capable of detecting \>5 pg/mL for each analyte.

Cell Proliferation {#s4f}
------------------

Lymphocyte proliferation was measured by a 5-Bromo-2′-deoxy uridine (BrdU) absorption and detection (Roche Diagnostics). In brief, purified CD4^+^ T cells were cultured at a density of 5×10^6^ cells/mL, with 10^6^ mitomycin C-treated feeder cells/mL in complete medium containing 1 µM of PspA peptide at 37°C in 5% CO~2~. After 2 days of *ex vivo* antigen stimulation, cells were transferred to polystyrene 96 well plates (Corning Glass Work). 10 µL of BrdU labeling solution (10 µM final concentration per well) were added and incubated for 18 hours at 37°C with 5% CO~2~. The cells were then fixed and incubated with 100 µL of nuclease in each well for 30 minute at 37°C. The cells were washed with complete media and incubated with BrdU-POD solution for 30 minute at 37°C. BrdU incorporation was developed with an 2,2′--azino-bis 3- ethylbenzthiazoline-6-sulfonic acid (ABTS) solution and optical density (OD) was read at 450 nm. The proliferation index (PI) was calculated as follows. Antigen-specific CD4^+^ T cell proliferation was obtained by measuring 5-Bromo-2′-deoxy uridine (BrdU) incorporation, according to manufacturer\'s instructions (Roche Diagnostics). BrdU absorption or optical density at 450 nm (OD~450~) was detected using a scanning multi-well SpectraMax 250 spectrophotometer (Molecular Devices). PI = OD~450~ in peptide stimulated cell/OD~450~ in un-stimulated cells ×100. The results were expressed as mean ± the standard error mean (SEM) of the response of 3 replicate determinations from three independent experiments. Statistical significance was assessed by student\'s t test.

MHC Class II Epitope Prediction Using External Tools {#s4g}
----------------------------------------------------

IEDB (<http://www.immuneepitope.org/>), SYFPEITHI (<http://www.syfpeithi.de/>), SVMHC (<http://www.bs.informatik.unituebingen.de/SVMHC/>), RANKPEP (<http://bio.dfci.harvard.edu/RANKPEP/>), and MHCPred (<http://www.jenner.ac.uk/MHCPred>) external software(s) were used to predict peptide binding affinities to mouse I-A and I-E as well as HLA-DR, -DP and -DQ. In brief, for average relative binding (ARB) evaluation, 10-fold cross validation results stored at IEDB were used to estimate performance. Because the binding of peptides to MHC class II molecules is not dependent on exact size, derivation of MHC class II ARB matrices followed an iterative procedure. For the first iterative step, a matrix was generated from a set of nine-residue core sequences randomly obtained from each peptide sequence in the training set. For subsequent cycles, nine-residue core sequences were used to generate a matrix. The overall binding affinity of a peptide was predicted using the highest scoring nine-residue core sequence. For the SYFPEITHI prediction, we patched each testing peptide with three glycine residues at both ends before evaluation for prediction. This was recommended by the creators of SYFPEITHI method to ensure that all potential binders were correctly presented to the prediction algorithm. For all other methods, the original tested peptides were submitted directly for prediction. Peptide sequences were sent to web servers one at a time and predictions were extracted from the server\'s response. To assign a single prediction for peptides longer than nine amino acids in the context of tools predicting the affinity of 9 core-binding regions, we took the highest affinity prediction of all possible 9-mers within the longer peptide as the prediction result. For each MHC class II molecule whose binding can be predicted by three or more algorithms, the top three methods were selected that gave the best performance. For each method, peptides were tested and ranked by their scores with higher ranks for better binders. For each tested peptide, three ranks from different methods were taken and the median rank was taken as the consensus score. Peptides were classified into binders (IC~50~\<500 nM) and nonbinders (IC~50~≥500 nM), as practical cutoffs.

Statistics {#s4h}
----------

Data are expressed as the mean ± SEM and compared using a two-tailed student\'s *t*-test or an unpaired Mann Whitney U test. The results were analyzed using Microsoft Excel for Macintosh computers and were considered statistically significant if *p* values were less than 0.01. When cytokine or antibody levels were below the detection limit (BD), they were recorded as one-half the lower detection limit for statistical analysis.
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